Company: SUPN
Filing Date: 2025-04-30
Form Type: DEF 14A
Source: 0001104659-25-042531
Chunk: 54

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-04-30
Form: DEF 14A
Chunk 54
---
 ​ | ​ | ​                              | $ |   377,400 | ​ | ​ | ​ | ​                                                    | $ |   377,400 | ​ | ​ | ​ | ​                                                 | $ |   377,400 | ​ | ​ |
| ​                         | ​ | ​ | Bonus(3)                    | ​ | ​ | ​                              | $ |   129,361 | ​ | ​ | ​ | ​                                                    | $ |   129,361 | ​ | ​ | ​ | ​                                                 | $ |   129,361 | ​ | ​ |
| ​                         | ​ | ​ | Continuation of benefits(4) | ​ | ​ | ​                              | $ |    28,807 | ​ | ​ | ​ | ​                                                    | $ |    28,807 | ​ | ​ | ​ | ​                                                 | $ |    28,807 | ​ | ​ |
| ​                         | ​ | ​ | Total                       | ​ | ​ | ​                              | $ |   535,568 | ​ | ​ | ​ | ​                                                    | $ |   535,568 | ​ | ​ | ​ | ​                                                 | $ |   535,568 | ​ | ​ |

38

(1) Amount shown for bonus in connection with a change in control represents the bonus payment Mr. Khattar would have earned under his employment agreement based on the assumption that his employment terminated as of the last day of fiscal year 2024. The amount set forth in the table reflects the bonus paid to Mr. Khattar during 2024 under our annual cash incentive plan, which pertained to the 2023 fiscal year. (2) Amounts shown for continuation of benefits represent estimates for the continuation of COBRA insurance benefits afforded to Mr. Khattar and eligible family members in accordance with his employment agreement. (3) Amounts shown for bonus in connection with the Executive Retention Agreement represent the bonus payment to the executive based on a lump-sum payment equal to the most recent annual bonus received by the executive. The amount set forth in the table reflects the bonus paid to each executive during 2024 under our annual cash incentive plan, which pertained to the 2023 fiscal year. (4) Amounts shown for continuation of benefits represent estimates for the continuation of COBRA insurance benefits afforded to the executive officer and eligible family members in accordance with the Executive Retention Agreement. CEO Pay Ratio Pursuant to Section 953(b) of the